Related Experiment Video
Updated: Sep 4, 2025
04:44
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
20.2K
Toll-like receptor triggering in systemic sclerosis: time to target
1Biosciences, Durham University, Durham, UK.
Rheumatology (Oxford, England)
|July 21, 2022
Summary
Scleroderma (SSc) involves vascular issues, inflammation, and fibrosis. Toll-like receptors (TLRs) activation in SSc fibroblasts drives collagen production, contributing to disease pathogenesis and fibrosis.
Area of Science:
- Immunology
- Rheumatology
- Cell Biology
Background:
- Scleroderma (SSc) is a complex autoimmune disease characterized by vascular abnormalities, inflammation, and progressive fibrosis in the skin and lungs.
- Toll-like receptors (TLRs) are crucial in innate immunity, recognizing danger signals and initiating inflammatory responses.
- The interplay between inflammation and fibrosis is central to SSc pathogenesis, with fibroblast activation playing a key role.
Approach:
- This review synthesizes current evidence on the expression and function of TLRs in SSc.
- It examines the mechanisms by which TLR ligation on fibroblasts contributes to collagen production and fibrosis.
- The review also explores potential therapeutic strategies targeting TLRs to mitigate SSc-associated fibrosis.
Key Points:
- TLR activation on SSc fibroblasts directly stimulates collagen synthesis, a key feature of scleroderma.
- Damage-associated molecular patterns (DAMPs) are implicated in the fibrotic processes observed in SSc.
- Understanding TLR signaling pathways offers insights into disease mechanisms and potential therapeutic targets.
Conclusions:
- TLRs play a significant role in the pathogenesis of SSc, particularly in driving fibrosis.
- Targeting TLRs presents a promising therapeutic avenue for managing inflammation and fibrosis in SSc.
- Further research into TLR-mediated pathways could lead to novel treatments for scleroderma.
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
9.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.2K
01:24T Cell Types and Functions
1.4K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.4K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.7K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.7K
01:16TGF - β Signaling Pathway
7.6K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.6K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
224
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
224